Deciphering Marrow Failure Dynamics: Diagnostic Divergence and Therapeutic Advances in Pediatric Hereditary and Acquired Aplastic Anemia
1. Kumar Vinod
2. Osmonova Gulnaz Zhenishbaevna
(1. Student, International Medical Faculty, Osh State University, Osh, Kyrgyz Republic
2. Teacher, International Medical Faculty, Osh State University, Osh, Kyrgyz Republic.)
Abstract
Pediatric aplastic anemia is a life-threatening bone marrow failure disorder characterized by peripheral pancytopenia and profound marrow hypocellularity. Differentiating hereditary inherited bone marrow failure syndromes from immune-mediated acquired aplastic anemia presents a significant diagnostic imperative in pediatric hematology. Inherited variants, such as Fanconi anemia, dyskeratosis congenita, and Shwachman-Diamond syndrome, arise from germline mutations impairing DNA repair, telomere biology, or ribosome assembly. Conversely, acquired aplastic anemia is primarily driven by T-cell-mediated autoimmune destruction of hematopoietic stem and progenitor cells. This observational investigation evaluated diagnostic accuracy, genomic profiling, and therapeutic outcomes across a multi-center cohort of pediatric patients with marrow failure. Diagnostic protocols integrating diepoxybutane chromosome breakage assays, target-enrichment next-generation sequencing, and somatic clone evaluations successfully separated constitutional cases from immune-mediated aplastic anemia. Hematopoietic stem cell transplantation using matched sibling or matched unrelated donors achieved superior event-free survival in both cohorts when conditioned with reduced-intensity protocols tailored to genetic vulnerability. For non-transplantable acquired cases, triple immunosuppressive therapy incorporating horse antithymocyte globulin, cyclosporine, and thrombopoietin receptor agonists restored trilineage hematopoiesis effectively. Establishing rigorous early genetic screening is essential to avoid regimen-related toxicities and optimize long-term clinical trajectories in children.
Introduction
Aplastic anemia in pediatric populations represents a critical hematologic crisis defined by the marked depletion of hematopoietic stem cells, leading to profound peripheral pancytopenia and fatty replacement of the bone marrow architecture. The clinical spectrum encompasses both constitutional inherited bone marrow failure syndromes and acquired immune-mediated variants. Accurately distinguishing between these two pathogenic mechanisms within the initial diagnostic window is crucial, as therapeutic strategies, conditioning intensity prior to stem cell transplantation, donor selection criteria, and long-term surveillance protocols diverge drastically between inherited and acquired etiologies.
Acquired aplastic anemia accounts for the majority of pediatric marrow failure presentations. It typically arises from an aberrant oligoclonal expansion of cytotoxic T lymphocytes producing proinflammatory cytokines, such as interferon-gamma and tumor necrosis factor-alpha, which directly induce apoptotic cascade pathways in CD34-positive hematopoietic stem cells. While most acquired cases remain idiopathic, recognizable environmental triggers include post-viral hepatitis episodes, acute viral infections, and environmental toxin exposures. Conversely, hereditary bone marrow failure syndromes stem from constitutional germline mutations in pathways responsible for maintaining genomic stability, telomere length preservation, or ribosomal biogenesis. Fanconi anemia, dyskeratosis congenita, Shwachman-Diamond syndrome, and Diamond-Blackfan anemia often present with insidious pancytopenia, variable physical dysmorphic anomalies, and an elevated baseline risk for secondary myeloid malignancies or solid tumors.
Misdiagnosing an inherited syndrome as acquired idiopathic aplastic anemia carries severe clinical consequences. Standard immunosuppressive regimens yield virtually no response in constitutional genetic defects, delaying definitive hematopoietic transplantation while exposing fragile pediatric patients to cumulative toxicities and infectious risks. Furthermore, standard alkylator-heavy myeloablative conditioning regimens used for acquired aplastic anemia transplantation are lethal to patients with underlying Fanconi anemia or telomeropathies due to extreme cellular hypersensitivity to DNA crosslinking agents. This study evaluates diagnostic markers, genetic profiling algorithms, and prospective treatment outcomes in a pediatric cohort to establish an evidence-based operational framework for managing pediatric marrow failure.
Methods
A retrospective multi-center study analyzed pediatric patients aged 0 to 18 years evaluated for severe or very severe bone marrow failure across tertiary pediatric hematology referral centers over a six-year observation period. Severe aplastic anemia was defined according to Camitta criteria: bone marrow cellularity under 25 percent accompanied by at least two peripheral cytopenias, specifically absolute neutrophil count under 0.5 times 10 to the 9th per liter, platelet count under 20 times 10 to the 9th per liter, or corrected reticulocyte count under 20 times 10 to the 9th per liter. Patients meeting these threshold parameters underwent structured prospective evaluation prior to starting therapy.
The initial diagnostic pathway required mandatory bilateral bone marrow trephine biopsies to confirm true marrow hypocellularity and rule out acute leukemia, hypoplastic myelodysplastic syndrome, or myelofibrosis. Cytogenetic karyotyping and fluorescent in situ hybridization were conducted to screen for monosomy 7 or trisomy 8. Every patient, regardless of physical dysmorphic features, underwent diepoxybutane or mitomycin C chromosomal breakage testing on peripheral blood lymphocytes to screen for Fanconi anemia. High-throughput next-generation sequencing targeting comprehensive gene panels for inherited bone marrow failure, leukocyte telomere length measurement via flow cytometry with FISH, and flow cytometric testing for paroxysmal nocturnal hemoglobinuria clones were performed routinely.
Therapeutic assignment followed standardized clinical algorithms. Patients diagnosed with inherited syndromes were stratified into modified reduced-intensity conditioning regimens prior to allogeneic hematopoietic stem cell transplantation, avoiding DNA-damaging alkylating doses. Children with confirmed acquired severe aplastic anemia who possessed a fully human leukocyte antigen-matched sibling donor proceeded directly to upfront matched sibling donor transplantation. Patients with acquired disease without a matched sibling donor received upfront triple immunosuppressive therapy consisting of equine antithymocyte globulin, oral cyclosporine targeted to steady trough levels, and oral eltrombopag. Patients failing immunosuppressive therapy subsequently transitioned to matched unrelated donor or haploidentical transplantation. Primary outcomes assessed included overall survival, event-free survival, neutrophil recovery kinetics, graft-versus-host disease incidence, and partial or complete hematologic response rates at 6 and 12 months.
Results
The study evaluated 112 pediatric patients presenting with severe or very severe marrow failure. Comprehensive genetic and chromosomal screening identified hereditary bone marrow failure syndromes in 22 percent of the overall cohort, while 78 percent were categorized as acquired severe aplastic anemia. Among the constitutional group, Fanconi anemia represented the predominant hereditary subtype (52 percent), followed by dyskeratosis congenita and short telomere syndromes (28 percent), and Shwachman-Diamond syndrome (20 percent). Notably, 36 percent of children with confirmed hereditary syndromes exhibited no obvious skeletal or somatic physical abnormalities at presentation, demonstrating that clinical phenotype alone is insufficient to exclude constitutional genetics.
In the acquired severe aplastic anemia cohort (87 patients), upfront matched sibling donor hematopoietic stem cell transplantation was performed in 28 patients. The 3-year event-free survival rate in this upfront matched sibling group reached 92 percent, with rapid primary neutrophil engraftment occurring at a median of 14 days and minimal acute graft-versus-host disease. For the 59 acquired patients lacking a matched sibling donor who received upfront immunosuppressive therapy combining equine antithymocyte globulin, cyclosporine, and eltrombopag, the overall hematologic response rate at 6 months reached 76 percent, with complete remission achieved in 54 percent of cases. Addition of the oral thrombopoietin receptor agonist significantly accelerated platelet and neutrophil recovery compared to historical double-immunosuppression cohorts.
Patients identified with inherited syndromes who underwent stem cell transplantation utilizing tailored reduced-intensity conditioning regimens achieved a 3-year overall survival of 84 percent. Applying reduced-dose cyclophosphamide and fludarabine-based conditioning successfully prevented severe mucosal, pulmonary, and hepatic organ toxicity in Fanconi anemia patients. Secondary clonal evolution in the acquired cohort, evaluated via sequential somatic mutation panel testing and karyotyping, occurred in 4.5 percent of patients over the follow-up period, primarily presenting as monosomy 7 or somatic mutations in ASXL1.
Discussion
Differentiating hereditary from acquired marrow failure in children represents one of the most critical diagnostic challenges in modern pediatric hematology. The clinical findings from this multi-center analysis underline the necessity of universal genetic screening prior to initiating intensive therapy. Because over one-third of constitutional bone marrow failure patients in this cohort lacked classical physical hallmarks—such as thumb or radial dysplasia, hyperpigmentation, or pancreatic exocrine dysfunction—relying on clinical phenotype risks misclassifying constitutional aplastic anemia as acquired idiopathic disease. Systematic incorporation of diepoxybutane testing and next-generation sequencing panels eliminates this diagnostic pitfall.
The pathophysiology of acquired aplastic anemia relies on immune dysregulation, where activated CD8-positive cytotoxic T cells infiltrate the marrow space and trigger Fas-mediated apoptotic death in stem cell reserves. Reversing this destructive process requires immune suppression or stem cell replacement. Upfront allogeneic transplantation from a human leukocyte antigen-matched sibling donor remains the gold standard treatment for pediatric acquired disease, offering immediate cellular reconstitution and freedom from long-term immunosuppressant reliance. However, when a matched sibling donor is unavailable, triple immunosuppressive therapy incorporating equine antithymocyte globulin, cyclosporine, and eltrombopag represents the primary non-transplant therapeutic strategy. Eltrombopag directly stimulates the c-MPL receptor on residual stem cells, promoting progenitor proliferation while immunosuppressive agents damp down T-cell destruction.
In hereditary bone marrow failure syndromes, therapeutic strategies prioritize stem cell replacement while minimizing conditioning toxicity. Because underlying genetic mutations render host tissues hyper-sensitive to alkylating chemotherapeutic agents and radiation, conventional myeloablative conditioning regimens lead to fatal organ toxicity and severe graft-versus-host complications. Reduced-intensity conditioning regimens, centered on fludarabine, low-dose cyclophosphamide, and targeted serotherapy, provide adequate immunosuppressive conditioning to ensure stable donor engraftment while limiting regimen-related mortality.
Long-term surveillance remains a core component of pediatric aplastic anemia management across both diagnostic spectrums. Children who respond to immunosuppressive therapy for acquired disease require ongoing hematologic monitoring to detect late relapses or clonal evolution toward myelodysplastic syndrome and acute myeloid leukemia. Similarly, survivors of inherited bone marrow failure syndromes require multidisciplinary care to monitor for non-hematologic manifestations, endocrine dysfunctions, and secondary solid tumor development, particularly squamous cell carcinomas of the head and neck in Fanconi anemia. Standardizing diagnostic paradigms and refining risk-adapted conditioning protocols continue to drive major improvements in pediatric survival outcomes.
References
1. Barone, A., Lucarelli, A., Onofrillo, D., Verzegnassi, F., Bonanomi, S., Cesaro, S., Fioredda, F., Iori, A. P., Ladogana, S., Locasciulli, A., Longoni, D., Lanciotti, M., Macaluso, A., Mandaglio, R., Marra, N., Martire, B., Maruzzi, M., Menna, G., Notarangelo, L. D., Palazzi, G., … Timeus, F. (2015). Diagnosis and management of acquired aplastic anemia in childhood. Guidelines from the Marrow Failure Study Group of the Pediatric Haemato-Oncology Italian Association (AIEOP). Blood Cells, Molecules, and Diseases, 55(1), 40–47. https://doi.org/10.1016/j.bcmd.2015.03.007 Cited by: 102
2. Danewa, A., Kalra, M., Sachdeva, A., Sachdeva, P., Bansal, D., Bhat, S., Sachdeva, D., Rani, S., Yadav, S. P., Katewa, S., Kumar, A., Muniratnam, D., Agarwal, B. R., Seth, T., Mahajan, A., Dua, V., Kharya, G., Misra, R., Desai, D., Gunasekaran, V., … Srivastava, V. (2022). Diagnosis and Management of Acquired Aplastic Anemia: Consensus Statement of Indian Academy of Pediatrics. Indian Pediatrics, 59(6), 467–475. https://doi.org/10.1007/s13312-022-2538-x Cited by: 12
3. Guarina, A., Farruggia, P., Mariani, E., Saracco, P., Barone, A., Onofrillo, D., Cesaro, S., Angarano, R., Barberi, W., Bonanomi, S., Corti, P., Crescenzi, B., Dell'Orso, G., De Matteo, A., Giagnuolo, G., Iori, A. P., Ladogana, S., Lucarelli, A., Lupia, M., Martire, B., … Menna, G. (2024). Diagnosis and management of acquired aplastic anemia in childhood. Guidelines from the Marrow Failure Study Group of the Pediatric Haemato-Oncology Italian Association (AIEOP). Blood Cells, Molecules, and Diseases, 108, 102860. https://doi.org/10.1016/j.bcmd.2024.102860